Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

Kittyc803 Nov. 15 at 7:03 PM

$ATOS $CISO $SLS bored today looking for deals to play while we wait . My pick for short term pop of at least 100 % $OTLK second blah submitted. Approval looks over 90 % shortly . Put it on the list . Don’t throw rocks 🪨 or ban me 😆😆😆😆 promise im done ✔️ Have a good weekend

3 · Reply

Kittyc803 Nov. 15 at 4:41 PM

$ATOS While we waiting on Quay to deliver . Might wanna put $CAPS on your watch list . Small float , crazy revenues . Put it on your watch list just for the hell of it . Looks promising

2 · Reply

Bunster Nov. 15 at 5:31 AM

$ATOS PRIMES WEEK IN REVIEW pps 80c november 14 2025 pitifull stevie boy. WHY DONT U OWN UP TO IT NOT CREATING SHAREHOLDER VALUE IN YEARS? while taking millions in salary and stock options. HIGHLITE was 10q which prime gave u finanancial HIGHLITES as your shirpa, fda meeting next week.The beginning as a former good popular contributor night owl has put it as A HAIL MARY.

0 · Reply

MrLowellRedlingsFarquhar Nov. 15 at 4:43 AM

$ATOS https://www.youtube.com/watch?v=Ef6t4GtpLCc&feature=youtu.be

0 · Reply

JDAAT Nov. 15 at 3:42 AM

$ATOS next stop is $1.60

1 · Reply

Kittyc803 Nov. 15 at 2:19 AM

$ATOS We still have hope with FDA meeting . 🙏 Release the Kraken Doc LFG

1 · Reply

ALDERAANandON Nov. 14 at 10:29 PM

$ATOS My memory is hazy. Isn't this the company with a drug that has demonstrably reduced breast cancer tumor size in limited trials, that reduces breast density to help with imaging diagnosis, and has fewer side effects than the current standard of care?

1 · Reply

Warrens__Buffet_ Nov. 14 at 9:16 PM

$ATOS roughly 10 more days until Atossa receives a non-compliance letter from NASDAQ. Right back to where we started. Just an FYI

0 · Reply

NoSunshinewoRain Nov. 14 at 9:06 PM

$ATOS Big day Monday (FDA meeting) hoping we get some good news from it come December.

1 · Reply

FLNY Nov. 14 at 4:35 PM

$ATOS

1 · Reply

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 9 days ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 25 days ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 4 weeks ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 4 weeks ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 5 weeks ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 6 weeks ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 3 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 5 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 6 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 6 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 7 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 7 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 7 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 7 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 8 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 8 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 8 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 8 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 10 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 10 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 10 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 1 year ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 1 year ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 14, 2024, 5:08 PM EDT - 1 year ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 21, 2024, 11:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Jul 2, 2024, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Kittyc803 Nov. 15 at 7:03 PM

3 · Reply

Kittyc803 Nov. 15 at 4:41 PM

$ATOS While we waiting on Quay to deliver . Might wanna put $CAPS on your watch list . Small float , crazy revenues . Put it on your watch list just for the hell of it . Looks promising

2 · Reply

Bunster Nov. 15 at 5:31 AM

0 · Reply

MrLowellRedlingsFarquhar Nov. 15 at 4:43 AM

$ATOS https://www.youtube.com/watch?v=Ef6t4GtpLCc&feature=youtu.be

0 · Reply

JDAAT Nov. 15 at 3:42 AM

$ATOS next stop is $1.60

1 · Reply

Kittyc803 Nov. 15 at 2:19 AM

$ATOS We still have hope with FDA meeting . 🙏 Release the Kraken Doc LFG

1 · Reply

ALDERAANandON Nov. 14 at 10:29 PM

1 · Reply

Warrens__Buffet_ Nov. 14 at 9:16 PM

$ATOS roughly 10 more days until Atossa receives a non-compliance letter from NASDAQ. Right back to where we started. Just an FYI

0 · Reply

NoSunshinewoRain Nov. 14 at 9:06 PM

$ATOS Big day Monday (FDA meeting) hoping we get some good news from it come December.

1 · Reply

FLNY Nov. 14 at 4:35 PM

$ATOS

1 · Reply

JDAAT Nov. 14 at 3:42 PM

$ATOS

0 · Reply

DCalcote Nov. 14 at 3:03 PM

$ATOS

0 · Reply

scrappy_trader Nov. 14 at 2:29 PM

$ATOS - Dr on LinkedIn How to Start a Biotech Company—11 Key Steps Every Early-Stage Founder Should Follow By Sherri Gordon https://wewillcure.com/insights/entrepreneurship/how-to-start-a-biotech-company Steven Quay, MD, PhD, founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company addressing breast cancer and other breast conditions, advises not to be afraid of failure or changing direction. “You never learn from your successes,” said Dr. Quay, who has founded six startups and holds 92 issued U.S. patents. “Your successes were because you were a genius and you worked hard, but your failures are where you really learn things. There are 10,000 reasons a biotech company can go wrong, and there’s only one path through those that gets you to success.”

2 · Reply

Knowspicker3 Nov. 14 at 2:25 PM

$ATOS

0 · Reply

treespider23 Nov. 14 at 2:03 PM

$ATOS i just keep buying and buying and buying

1 · Reply

Jedea Nov. 14 at 1:46 PM

$ATOS 🙏🙏🙏🙏

0 · Reply

Kittyc803 Nov. 14 at 1:19 PM

$ATOS

0 · Reply

dcajic2 Nov. 14 at 1:13 PM

$ATOS what is possibly bullish yet? Years and years away from possibly getting FDA approval. After well over a decade of research they are still in phase 2. They will not get full results for a small study until end of next year. They are still enrolling a bigger phase 2 study . There are a few companies that are much closer to getting FDA approval for breast cancer. Things are looking not good

0 · Reply

Lucci80 Nov. 14 at 12:58 PM

$ATOS

0 · Reply

JDAAT Nov. 14 at 3:57 AM

$ATOS now is the best time to buy shares

0 · Reply

MissNaser Nov. 14 at 12:54 AM

$ATOS there hope everyone !! https://www.tipranks.com/news/ratings/atossa-therapeutics-strategic-advancements-in-breast-cancer-treatment-drive-buy-rating-ratings

4 · Reply

Jcb1990 Nov. 14 at 12:44 AM

$ATOS let’s get compliant and then drop to 79’cents a week later. Can’t make this shit up.

0 · Reply

Market Cap	103.69M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	482,900
Avg Vol	930,510
Day's Range	N/A - N/A
Shares Out	129.17M
Stochastic %K	25%
Beta	0.99
Analysts	Sell
Price Target	$5.69